Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antigens and immunoassays for diagnosing Chagas' disease

an immunoassay and antibody technology, applied in the field of antibodies and immunoassays for diagnosing chagas' disease, can solve the problem of not being able to detect enough sensitive single tests, and achieve the effect of high sensitive and specificity

Inactive Publication Date: 2003-06-12
INNOGENETICS NV
View PDF0 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It is clear from the above that no single test is sufficiently sensitive to prevent transfusion transmission of Chagas' disease which has become the major route of transmission for this infection.
Current screening tests are insensitive, nor-specific and yield conflicting results, while convenient confirmatory assays do not exist.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antigens and immunoassays for diagnosing Chagas' disease
  • Antigens and immunoassays for diagnosing Chagas' disease

Examples

Experimental program
Comparison scheme
Effect test

examples

[0034] Evaluating a Recombinant and Peptide Antigen Line Immunoassay for Chagas' Disease: the INNO-LIA Chagas Antibody (Ab) Assay.

[0035] a. Materials and Methods

[0036] Study Population

[0037] The 1062 sera employed in this retrospective study were obtained from patients and healthy residents of four Brazilian regions endemic for Chagas' disease: 261 sera were from the state of Minas Gerais (municipality Virgem da Lapa) where the cardiac and digestive forms of the disease are frequent; 465 and 253 sera were obtained in the hinterlands of Paraiba and Piaui, respectively, where the indeterminate form of the disease is common; and 83 sera were from the Amazon (municipality of Barcellos) where Chagas' disease is emerging. Most of the blood samples originated from patients who have been participating in long-term follow-up studies for 2-20 years. Serologic analysis was performed using several immunological methods (see below). In addition, the presence of the parasite could be demonstrated...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
reactivityaaaaaaaaaa
secondary structureaaaaaaaaaa
compositionaaaaaaaaaa
Login to View More

Abstract

Transfusion of contaminated blood has become the major route of transmission for Chagas' disease. Current screening tests are insensitive and yield conflicting results, while confirmatory assays do not exist. The present invention relates to antigens and their use for serological diagnosis of Chagas' disease. More specifically, the present invention concerns assays which are able to reliably and accurately detect the presence of antibodies to various specific antigens of Trypanosoma cruzi in a highly sensitive and specific manner.

Description

FIELD OF THE INVENTION[0001] The present invention relates generally to sets of at least 6 recombinant and / or synthetic peptides derived from Trypanosoma cruzi proteins which are used for diagnosing Chagas' disease in a highly sensitive and specific manner. More specifically, the present invention relates to peptides derived from the T. cruzi antigens SAPA, CRA, FRA, TcD, Tc24, Ag39 and MAP which are used in a confirmatory immunoassay and concerns kits comprising the latter peptides.[0002] BACKGROUND OF THE INVENTION[0003] Chagas' disease is endemic throughout Latin America and a major cause of morbidity and mortality in those countries affected. Approximately 16-18 million people are infected, and about 50,000 patients die each year from the condition (Carvalho et al., 1993). Its etiologic agent, the protozoan parasite Trypanosoma cruzi, is naturally transmitted by various species of triatomine bugs. Disease transmission occurs when infectious forms of the parasite are deposited du...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K14/44G01N33/569
CPCC07K14/44G01N33/56905Y10S530/806Y10S435/975Y10S530/822A61P33/02Y02A50/30
Inventor ZREIN, MAAN
Owner INNOGENETICS NV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com